Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03189108 · ClinicalTrials.gov registry record
Collection of Malignant Ascites, Pleural Fluid, and Blood From People With Solid Tumors
A clinical trial, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- 22
- Enrollment target
NCT03189108: Clinical Trial study, sponsored by National Cancer Institute (NCI).
NCT03189108 is a clinical trial that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03189108 was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- 22 participants
- Enrollment target
Study Summary
Background: Researchers want to study fluids and blood of people with cancer. The fluids are from the abdomen and around the lungs. Studying these might help researchers learn about the biology of cancer. This may lead to better ways to treat cancer. Objectives: To study the biology of cancer. Eligibility: Adults 18 and older with malignant solid tumors. Design: Participants will be screened with medical history, blood tests, and confirmation of diagnosis. Participants will have samples taken at regularly scheduled procedures. Fluids from the abdomen and/or lungs will be taken as part of the procedures. Blood will be taken separately. Participants may be asked to give more samples at future procedures.
Primary Outcome
Experimental - Translational study outcomes from the collection/analysis of blood samples; and ascites and pleural effusion samples from patients with solid tumor malignancies.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2017-05-22 |
| Est. Completion | 2023-05-18 |
Why NCT03189108 stopped before completion
NCT03189108 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 22 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT03189108 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03189108 about?
NCT03189108 is a clinical study titled "Collection of Malignant Ascites, Pleural Fluid, and Blood From People With Solid Tumors". Background: Researchers want to study fluids and blood of people with cancer. The fluids are from the abdomen and around the lungs. Studying these might help researchers learn about the biology of cancer. This may lead to better ways to treat cancer. Objectives: To study the biology of cancer. E...
What is the current status of trial NCT03189108?
This trial is currently terminated. The enrollment target is 22 participants. The study started on 2017-05-22. Estimated completion is 2023-05-18.
Who is sponsoring clinical trial NCT03189108?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI